Prelude Therapeutics Advances Two Key Oncology Programs with IND Clearances
Event summary
- Prelude received FDA IND clearance for PRT12396, a mutant-selective JAK2V617F inhibitor, in Q1 2026.
- Phase 1 study for PRT12396 in polycythemia vera and myelofibrosis patients to begin in Q2 2026.
- IND filing for PRT13722, a highly-selective oral KAT6A degrader, planned for mid-2026 with Phase 1 study initiation in H2 2026.
- Company has $106.4 million in cash as of December 31, 2025, with runway into Q2 2027.
- R&D expenses decreased to $94.3 million in 2025 from $118.0 million in 2024.
The big picture
Prelude Therapeutics is advancing its precision oncology pipeline with two key programs targeting myeloproliferative neoplasms and ER+ breast cancer. The company's strategic focus on mutant-selective inhibitors and targeted protein degradation aligns with broader industry trends toward more precise and effective cancer treatments. With a cash runway extending into 2027, Prelude aims to position itself for potential key data catalysts in 2027, which could attract further investment or partnership opportunities.
What we're watching
- Clinical Execution
- Whether Prelude can successfully initiate and complete Phase 1 studies for both PRT12396 and PRT13722 within 2026.
- Financial Sustainability
- The pace at which Prelude burns through its $106.4 million cash reserve and potential need for additional funding.
- Partnership Dynamics
- How the exclusive option agreement with Incyte and expanded collaboration with AbCellera Biologics will impact Prelude's strategic positioning.
Related topics